Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025.
Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET).
The Company invites investors to join the event via live webcast, which will be available on the Investor Relations section of its website at investors.insulet.com under "Events and Presentations." A replay of the webcast and the related slide presentations will be available on the Company's website following the event. In-person attendance is by invitation only and registration will be required.
About Insulet Corporation:
Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310508888/en/
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7718
[email protected]
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
[email protected]